Table 1.
Performances of three methods on five kinase inhibitors
| Drug |
iDTP (positive signature) |
iDTPnd (positive + negative signature) |
Baseline model (sequence similarity) |
|||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | Sensitivity | Specificity | Sensitivity | Specificity | |
| Sorafenib | 81% | 33% | 68% | 59% | 42% | 31% |
| Imatinib | 3% | 94% | 55% | 54% | 32% | 17% |
| Dasatinib | 2% | 99% | 42% | 57% | 29% | 18% |
| Sunitinib | 63% | 67% | 46% | 50% | 26% | 23% |
| Pazopanib | 4% | 95% | 50% | 55% | 32% | 40% |
| Average (±SD) | 31% (±34%) | 78% (±25%) | 52% (±9%) | 55% (±3%) | 32% (±5%) | 26% (±9%) |
Note: SD, standard deviation.